Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.
The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization’s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.
The global Non-Invasive Cancer Diagnostics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Non-Invasive Cancer Diagnostics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Non-Invasive Cancer Diagnostics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Non-Invasive Cancer Diagnostics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Non-Invasive Cancer Diagnostics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Quest Diagnostics Inc
Cancer, Genetics Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
Segment by Regions
Segment by Type
Segment by Application